论文部分内容阅读
目的 S探讨阿托伐他汀和普伐他汀对原发性高脂血症患者血糖的影响。方法 400例原发性高脂血症患者随机分为阿托伐他汀组和普伐他汀组各200例。阿托伐他汀组患者口服阿托伐他汀10 mg治疗,1次/d;普伐他汀组患者则口服普伐他汀40 mg治疗。于治疗前和治疗6、12、18个月分别检测患者血脂和血糖水平,观察新发糖尿病的情况。结果阿托伐他汀组患者治疗12、18个月后FPG和Hb A1c水平显著高于对照组(P<0.05)。阿托伐他汀组患者新发糖尿病率为11.00%,显著高于普伐他汀组的5.50%(P<0.05)。结论长期服用阿托伐他汀新发糖尿病率可能高于普伐他汀。
Objective To investigate the effects of atorvastatin and pravastatin on blood glucose in patients with primary hyperlipidemia. Methods 400 patients with primary hyperlipidemia were randomly divided into atorvastatin group and pravastatin group of 200 cases. Patients in the atorvastatin group received oral atorvastatin 10 mg once daily, while patients in the pravastatin group received pravastatin 40 mg orally. Patients’ blood lipids and blood glucose levels were measured before treatment and at 6, 12, and 18 months respectively. The incidence of new-onset diabetes was observed. Results The levels of FPG and Hb A1c in atorvastatin group after 12 and 18 months treatment were significantly higher than those in control group (P <0.05). The rate of new-onset diabetes in the atorvastatin group was 11.00%, significantly higher than that in the pravastatin group (5.50%, P <0.05). Conclusion Long-term use of atorvastatin new diabetes may be higher than pravastatin.